Dataset Information


International guidelines on stage III N2 nonsmall cell lung cancer: surgery or radiotherapy?

ABSTRACT: Stage III N2 nonsmall cell lung cancer (NSCLC) is a complex disease with poor treatment outcomes. For patients in whom the disease is considered technically resectable, the main treatment options include surgery (with neoadjuvant or adjuvant chemotherapy/neoadjuvant chemoradiotherapy (CRT)) or CRT followed by adjuvant immunotherapy (dependent on programmed death ligand 1 status). As there is no clear evidence demonstrating a survival benefit between these options, patient preference plays an important role. A lack of a consensus definition of resectability of N2 disease adds to the complexity of the decision-making process. We compared 10 international guidelines on the treatment of NSCLC to investigate the recommendations on preoperatively diagnosed stage III N2 NSCLC. This comparison simplified the treatment paths to multimodal therapy based on surgery or radiotherapy (RT). We analysed factors relevant to decision-making within these guidelines. Overall, for nonbulky mediastinal lymph node involvement there was no clear preference between surgery and CRT. With increasing extent of mediastinal nodal disease, a tendency towards multimodal treatment based on RT was identified. In multiple scenarios, surgery or RT-based treatments are feasible and patient involvement in decision-making is critical.


PROVIDER: S-EPMC7024765 | BioStudies | 2020-01-01

SECONDARY ACCESSION(S): 10.18632/oncotarget.16471

REPOSITORIES: biostudies

altmetric image


Definitive radiochemotherapy versus surgery within multimodality treatment in stage III non-small cell lung cancer (NSCLC) - a cumulative meta-analysis of the randomized evidence.

Pöttgen Christoph C   Eberhardt Wilfried W   Stamatis Georgios G   Stuschke Martin M  

Oncotarget 20170601 25

Randomized trials were analyzed comparing surgery with definitive radiotherapy as local curative treatment options within the framework of different multimodality treatments for patients with locally advanced non-small cell lung cancer (NSCLC). Endpoints for comparison of treatment results were overall survival, progression-free survival, and toxicity.Hazard ratios (HR) were taken to measure treatment effects and pooled using a random effects model.Overall survival was not significantly differen  ...[more]

Similar Datasets

2017-01-01 | S-EPMC5398511 | BioStudies
2017-01-01 | S-EPMC5398352 | BioStudies
2019-01-01 | S-EPMC6734655 | BioStudies
1000-01-01 | S-EPMC6219254 | BioStudies
2020-01-01 | S-EPMC7086160 | BioStudies
2019-01-01 | S-EPMC6603377 | BioStudies
2013-01-01 | S-EPMC4041407 | BioStudies
2018-03-12 | PXD008436 | Pride
2018-01-01 | S-EPMC6002839 | BioStudies
2018-01-01 | S-EPMC5960166 | BioStudies